Evidence map›Paper›PMID 39876875›Full record

ArticleJournal of the Endocrine Society2025

Assessing and Managing Primary Hyperparathyroidism and Fracture Risk in England: A Survey of Medical Professionals.

Kaiyang Song, Rohit Vijjhalwar, Mo Aye, Alexander N Comninos, Marian Schini, Afroze Abbas, Neil Gittoes, Muhammad Kassim Javaid

Abstract read
In one paragraph

Article in Journal of the Endocrine Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kaiyang SongMedical Sciences Division, University of Oxford, Oxford OX3 9DU, UK.
Rohit VijjhalwarMedical Sciences Division, University of Oxford, Oxford OX3 9DU, UK.
Mo AyeCentre for Metabolic Bone Diseases, Hull Royal Infirmary, Hull HU3 2JZ, UK.
Alexander N ComninosEndocrine Bone Unit, Imperial College Healthcare NHS Trust, London W2 1NY, UK.ORCID https://orcid.org/0000-0002-7104-2297
Marian SchiniDivision of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield S10 2TN, UK.ORCID https://orcid.org/0000-0003-2204-2095
Afroze AbbasLeeds Centre of Endocrinology and Diabetes, Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, UK.ORCID https://orcid.org/0000-0003-2497-6887
Neil GittoesCentre for Endocrinology, Diabetes and Metabolism, Queen Elizabeth Hospital and University of Birmingham, Birmingham B15 2GW, UK.
Muhammad Kassim JavaidNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK.ORCID https://orcid.org/0000-0001-7985-0048

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To describe diagnostic approaches and management strategies for patients with primary hyperparathyroidism (PHPT) and recent fracture in England. Methods: We developed a survey based on a patient at high fracture risk and a new diagnosis of probable PHPT. The survey was circulated among 50 secondary care professionals identified by the Society for Endocrinology Calcium and Bone special interest group. Descriptive statistics, combinatorial, and thematic analyses were employed. Results: In the patient with hyperparathyroidism and a recent fracture, 54% of respondents favoured a 24-hour urinary calcium: creatinine clearance ratio, with 85% opting to do so after correcting vitamin D levels. Thirty-two percent (16/50) preferred the spot urinary calcium:creatinine clearance ratio, as a random test (56%, n = 9/16). Ninety-six percent of the respondents agreed they would include a fracture risk assessment in their management plan. Eighty-five percent of the respondents selected dual-energy X-ray absorptiometry scans of the lumbar spine, total hip, and femoral neck as the most popular choice. Before initiating antiosteoporotic medications (AOMs), 94% of the respondents preferred correcting vitamin D levels with diverse regimens. IV zoledronate acid was the preferred AOM, and 58% (n = 29/50) supported cinacalcet usage if the patient was ineligible for parathyroid surgery, while 26% (n = 13/50) opposed cinacalcet use entirely. No significant correlation was found between status as an endocrinology consultant or working in a tertiary care hospital and these management preferences. Main Conclusion: This study of National Health Service medical staff identified highly-varied clinical practices in managing PHPT in the setting of high fracture risk, highlighting the need for pragmatic guidelines and wider education.

Indexed as

antiosteoporotic medicationfracturehyperparathyroidismsurvey

Identifiers

PMID39876875
PMCPMC11772554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.